Sarcopenia
Conditions
Interventions
Experimental Group (Based on Skeletal Muscle Mass):Dosing of cisatracurium based on skeletal muscle mass.
Control Group (Overall Cohort Group):Dosing of cisatracurium based on body weight.
Sponsors
The First Affiliated Hospital of Chengdu Medical College
Eligibility
Sex/Gender
All
Age
65 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Elderly patients (>=65 years) with sarcopenia scheduled to undergo general anesthesia at The First Affiliated Hospital of Chengdu Medical College; 2.American Society of Anesthesiologists (ASA) physical status classification of II - IV; 3.All subjects have provided signed informed consent; 4. Able to undergo body composition analysis via the InBody S10 Bioelectrical Impedance Analysis (BIA) device: meaning the body must be free of metal implants and cardiac pacemakers, etc.
Exclusion criteria
Exclusion criteria: 1. Patients with contraindications to general anesthesia or tracheal intubation, or those with a previous history of adverse anesthesia events; 2. Patients with known or suspected allergy or contraindications to Propofol Injection, Cisatracurium Besylate, opioids, or related drugs; 3.Patients assessed preoperatively as having a difficult airway or judged to be difficult for tracheal intubation (as assessed by an anesthesiologist); 4.Patients with a history of substance abuse or long-term use of anesthetic, sedative, analgesic drugs, or alcohol; 5.Patients with a previous history of psychiatric disorders; 6.Patients who have participated in any drug clinical trials within one month prior to screening; 7.Patients taking medications known to affect the pharmacodynamics of Cisatracurium Besylate, such as Carbamazepine, Phenytoin Sodium, etc.; 8.Patients with hepatic diseases, or other known disorders that may interfere with the distribution or excretion of Cisatracurium Besylate; 9.Patients with neuromuscular diseases; 10.Patients from whom informed consent could not be obtained.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of residual neuromuscular blockade; | — |
Countries
China
Contacts
Public ContactWang Li
The First Affiliated Hospital of Chengdu Medical College,Department of Anesthesiology
Outcome results
None listed